Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487403 | 1.00 | PGR (0.44) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL1901373 | 0.83 | ALDH1A1 (0.42) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL8396014 | 0.82 | PGR (0.66) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL11326826 | 0.82 | PGR (0.66) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL19628769 | 0.82 | PGR (0.66) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL10793803 | 0.81 | UGT2B7 (0.40) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL3356237 | 0.80 | SRD5A2 (0.41) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL3884305 | 0.79 | CYP17A1 (0.45) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL6510753 | 0.79 | PGR (0.46) | PGRALDH1A1CYP3A4CYP2C19AR | |
| SCHEMBL7349628 | 0.79 | PGR (0.46) | PGRALDH1A1CYP3A4CYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505983-A2 | ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED DISORDERS | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1469884-A1 | ALDOSTERONE ANTAGONIST AND NON-STEROIDAL ANTI-INFLAMMATORY AGENT COMBINATION THERAPY TO PREVENT OR TREAT CARDIOVASCULAR DISORDERS | Pharmacia Corporation (US) | 2004-10-27 | — | — | EP | claimed |
| EP-1469862-A2 | ALDOSTERONE RECEPTOR ANTAGONIST AND ALPHA-ADRENERGIC MODULATING AGENT COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR CONDITIONS | Pharmacia Corporation (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2004082636-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004082637-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN ENDOTHELIN RECEPTOR ANTAGONIST AND/OR ENDOTHELIN CONVERTING ENZYME INHIBITOR | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| EP-1455795-A1 | METHOD OF TREATING OPHTHALMIC DISORDERS WITH EPOXY-STEROIDAL ALDOSTERONE RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2004-09-15 | — | — | EP | claimed |
| WO-2004073602-A2 | ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED DISORDERS | PHARMACIA CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040102424-A1 | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20040053903-A1 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist | G.D. SEARLE & CO. | 2004-03-18 | — | — | US | claimed |
| US-20040037806-A1 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | PHARMACIA CORPORATION | 2004-02-26 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| WO-2002009760-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| WO-2001095893-A1 | USE OF AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROPHYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| EP-0831910-B1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | SEARLE & CO (US) | 2001-11-21 | — | — | EP | claimed |
| EP-1126880-A2 | COMBINATION THERAPY OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ALDOSTERONE ANTAGONIST FOR REDUCING MORBIDITY AND MORTALITY FROM CARDIOVASCULAR DISEASE | G.D. SEARLE & CO. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2001034132-A2 | USE OF AN ALDOSTERONE ANTAGONIST FOR TREATING RESTENOSIS | PHARMACIA CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2000027380-A2 | COMBINATION THERAPY OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ALDOSTERONE ANTAGONIST FOR REDUCING MORBIDITY AND MORTALITY FROM CARDIOVASCULAR DISEASE | G.D. SEARLE & CO. (US) | 2000-05-18 | — | — | WO | claimed |
| EP-0831910-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053903-A1 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist | NR3C2, AGTR2, AGTR1 | PGR 487/4885ALDH1A1 1208/4885CYP3A4 332/4885 |
| US-20040102424-A1 | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | NR3C2, CYP21A2, REN | PGR 1165/4885ALDH1A1 834/4885CYP3A4 1116/4885 |
| US-20040037806-A1 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | NR3C2, IL1RN, SERPINA6 | PGR 2786/4885ALDH1A1 2374/4885CYP3A4 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.